Expression and adjuvant effects of the fusion peptide TBP5.
- Author:
Chen WANG
;
Xiangling GUO
;
Xiaokang LI
;
Tingcai WU
;
Deyuan LI
;
Puyan CHEN
- Publication Type:Journal Article
- MeSH:
Adjuvants, Immunologic;
pharmacology;
Animals;
Antibodies, Viral;
blood;
Cell Proliferation;
drug effects;
Influenza A Virus, H9N2 Subtype;
drug effects;
physiology;
Influenza Vaccines;
immunology;
Interferon-gamma;
immunology;
Interleukin-4;
immunology;
Lymphocytes;
drug effects;
Mice;
Oligopeptides;
immunology;
Orthomyxoviridae Infections;
drug therapy;
Recombinant Fusion Proteins;
immunology;
Spleen;
cytology;
Thymopentin;
immunology;
Thymus Gland;
cytology;
Vaccines, Inactivated;
immunology;
Virus Replication
- From:
Chinese Journal of Biotechnology
2015;31(5):648-658
- CountryChina
- Language:Chinese
-
Abstract:
Thymopentin (TP5) and bursopentin (BP5) are both immunopotentiators. To explore whether the TP5-BP5 fusion peptide (TBP5) has adjuvant activity or not, we cloned the TBP5 gene and confirmed that the TBP5 gene in a recombinant prokaryotic expression plasmid was successfully expressed in Escherichia coli BL21. TBP5 significantly promoted the proliferation of thymic and splenic lymphocytes of mice. The potential adjuvant activity of the TBP5 was examined in mice by coinjecting TBP5 and H9N2 avian influenza virus (AIV) inactivated vaccine. HI antibody titers, HA antibodies and cytokines levels (IL-4 and IFN-γ) were determined. We found that TBP5 markedly elevated serum HI titers and HA antibody levels, induced the secretion of both IL-4 and IFN-γ cytokines. Furthermore, virus challenge experiments confirmed that TBP5 contributed to inhibition replication of the virus [H9N2 AIV (A/chicken/Jiangsu/NJ07/05)] from mouse lungs. Altogether, these findings suggest that TBP5 may be an effective adjuvant for avian vaccine and that this study provides a reference for further research on new vaccine adjuvants.
